FDA Approves Rocket Pharma Kresladi: First Gene Therapy for LAD-I

Conventional wisdom in gene therapy holds that a first commercial approval is primarily a revenue event. For Rocket Pharmaceuticals, the FDA's March 26, 2026 accelerated approval of Kresladi (marnetegragene autotemcel) is something more structurally significant: a manufacturing validation. Rocket's initial BLA was rejected in June 2024 via a Complete Response Letter citing Chemistry, Manufacturing, and Controls deficiencies — the same class of objection that has stalled or terminated gene therapy programs at bluebird bio, Passage Bio, and others. The successful resubmission and approval two years later signals that Rocket has navigated the FDA's evolving living-cell medicine standards, setting a documented precedent that competitors and regulators will both reference. The core fact is this: the FDA approved Kresladi on March 26, 2026 — two days ahead of its March 28 PDUFA date — making it the first FDA-approved gene therapy for severe Leukocyte Adhesion Deficiency Type I and Rocket's first commercial product.

The autologous gene therapy market sits at a structural inflection point. The broader cell and gene therapy sector was valued at approximately $19 billion in 2024 and is projected to grow at a CAGR of roughly 15%–17% through 2030, according to analyst consensus tracked by EvaluatePharma and GlobalData (these aggregate figures could not be independently verified at time of publication). Within that arena, autologous hematopoietic stem cell therapies occupy a high-complexity, high-margin niche where manufacturing capability — not scientific novelty — is the primary competitive barrier. The dominant players across rare pediatric indications include bluebird bio (approved for sickle cell disease and beta-thalassemia), Orchard Therapeutics (acquired by Kyowa Kirin), AVROBIO (now dissolved), and Rocket itself. The structural forces shaping competition are threefold: the FDA's tightening CMC expectations for lentiviral vector products, the finite global capacity of GMP-grade vector manufacturing facilities, and the growing concentration of payer scrutiny on single-administration therapies priced in the seven-figure range.

Kresladi is an autologous cell therapy manufactured by harvesting a patient's hematopoietic stem cells, genetically modifying them via lentiviral vector to introduce functional copies of the ITGB2 gene, and reinfusing them following conditioning. The mechanism targets the root cause of LAD-I: loss-of-function mutations in ITGB2 that deplete CD18, a protein required for leukocyte adhesion and tissue migration — the cellular machinery that confines and clears infections and initiates wound repair. Without it, children face recurrent, life-threatening bacterial infections and near-uniform early mortality absent allogeneic transplant. The pivotal Phase 1/2 global clinical trial reported a 100% overall survival rate across all enrolled patients at a minimum of one year post-treatment and through the full follow-up period; the trial met all primary and secondary endpoints, with significant infection incidence declining substantially versus pre-treatment baselines and measurable improvements in skin lesion resolution and wound healing (FDA press release, March 26, 2026). The FDA granted accelerated approval alongside a Rare Pediatric Disease Priority Review Voucher; continued approval is contingent on confirmatory post-marketing studies.

Three converging forces made this approval possible in March 2026 rather than at the initial June 2024 BLA. First, the FDA's CMC guidance for ex vivo lentiviral vector products has matured considerably since 2022, giving sponsors a clearer remediation roadmap — Rocket's resubmission addressed the agency's specific CMC requests, and the acceptance of that resubmission in October 2025 (BusinessWire, October 13, 2025) confirmed the path was navigable. Second, GMP vector manufacturing capacity has expanded meaningfully since 2022 as CDMOs including Lonza, Thermo Fisher's Brammer Bio, and Oxford Biomedica scaled lentiviral production lines, reducing the single-batch failure risk that historically amplified CMC concerns. Third, the FDA's accelerated approval pathway, deployed here on the basis of the Phase 1/2 surrogate endpoint data, gave regulators a mechanism to deliver access for a near-uniformly fatal pediatric disease without waiting for a randomized confirmatory dataset. The precedent most directly analogous is bluebird bio's Zynteglo (betibeglogene autotemcel), which navigated a comparable CMC-driven delay before receiving FDA approval in August 2022 — and whose eventual pricing and reimbursement trajectory now provides Rocket with both a commercial template and a cautionary data point.

The competitive implications of this approval operate on two distinct levels. At the asset level, Kresladi's commercial ceiling is structurally constrained: LAD-I affects approximately one in one million people, with Rocket estimating roughly 25 new U.S. cases annually. Leerink Partners analyst Mani Foroohar has stated explicitly that Kresladi will not be a significant revenue driver. The more material near-term financial event is PRV monetization — Rare Pediatric Disease PRVs have traded in the $100M–$150M range in recent secondary market transactions, representing a potential non-dilutive capital injection against a company whose pipeline burn is substantial. At the platform level, the approval functions as a CMC credentialing event for Rocket's broader lentiviral program: RP-L201 for Pyruvate Kinase Deficiency, RP-L301 for LAD-II, and the AAV-based RP-A501 for Danon disease all benefit from the demonstrated ability to satisfy the FDA's living-cell manufacturing standards. For rival programs still under CMC review, Rocket's resubmission package — while not public — will be studied by FDA reviewers as a benchmark, compressing review cycles for well-prepared sponsors and raising the bar for those that are not.

Our read: Kresladi's approval is less a commercial launch than a manufacturing certification that unlocks the rest of Rocket's valuation stack. The PRV is the most time-sensitive asset — the secondary market window for maximum PRV value tends to narrow as competing vouchers enter supply, and a Q2 2026 sale at the high end of the $100M–$150M historical range would represent meaningful runway extension. The confirmatory trial design, which Rocket must submit as a condition of accelerated approval, will test the company's ability to enroll a statistically meaningful cohort in a disease with 25 annual U.S. cases — a scientific and logistical challenge that analysts should model carefully. The single largest value driver remains the RP-A501 clinical hold for Danon disease: resolution would represent the most significant rerating catalyst in the company's near-term history, while a permanent hold or program termination would substantially alter the pipeline narrative. Companies building autologous lentiviral programs should treat Rocket's CMC resubmission as a reference architecture and pressure-test their own manufacturing documentation against it before their next IND or BLA submission window.

Four signals define the forward monitoring set for decision-makers tracking this space. First, PRV sale announcement: watch for a Rocket IR disclosure in Q2 2026 — a transaction above $130M would signal continued strong PRV demand from large pharma seeking to accelerate pipeline reviews, while a sub-$100M transaction would indicate market saturation from competing voucher supply. Second, RP-A501 clinical hold resolution: the FDA has not disclosed a timeline; any communication from Rocket referencing a Type A meeting with the agency would indicate active engagement and likely precede a hold-lifting announcement by 60–90 days. Third, Kresladi list price and first payer contract: the disclosed price will establish a reimbursement reference point for the broader autologous HSC therapy market — a list price above $3M would test payer tolerance in a category already under Congressional scrutiny, while outcomes-based contract terms would signal a maturing access model. Fourth, confirmatory trial IND or protocol submission: the FDA's accelerated approval condition requires Rocket to verify clinical benefit in post-marketing studies; the design of that trial — particularly its primary endpoint and enrollment projections — will determine whether the confirmatory burden is tractable or represents a latent regulatory risk to the approval's durability.